Moderate to Severe Major Depressive Disorder – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036
- Published Date : June 15, 2026
- Updated On : September 4, 2026
- Pages : 154
Moderate to Severe Dry Eye Disease Market Outlook and Forecast
Thelansis’s “Moderate to Severe Dry Eye Disease (DED) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Moderate to Severe Dry Eye Disease treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
Moderate to Severe Dry Eye Disease Overview
Moderate to severe dry eye disease is a multifactorial disorder of the ocular surface characterized by loss of tear-film homeostasis, tear instability, inflammation, and, in some patients, epithelial damage. Meibomian gland dysfunction, aqueous deficiency, and neurosensory abnormalities contribute to different disease phenotypes and can produce discomfort, burning, photophobia, and fluctuating vision. Artificial tears remain foundational, but management has expanded substantially beyond lubrication to include anti-inflammatory therapies, tear-evaporation control, and stimulation of endogenous tearing. Established treatments now include cyclosporine, lifitegrast, perfluorohexyloctane, and the cholinergic nasal spray varenicline. The treatment landscape broadened further in 2025 with FDA approval of acoltremon, a TRPM8 agonist that stimulates tear production and improved tear-production endpoints in randomized trials. Next-generation development is increasingly focused on phenotype-specific mechanisms, including kinase inhibition and other approaches targeting ocular-surface inflammation, tear secretion, and glandular dysfunction. OT202, a dual SYK/VEGFR-2 inhibitor, demonstrated activity in a 2026 Phase 2 study and has entered Phase 3 development. For stakeholders, moderate to severe DED represents an increasingly segmented therapeutic market in which the next advances are likely to come from matching mechanism to phenotype and achieving more durable restoration of tear-film and ocular-surface homeostasis.
Geography coverage:
G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven by robust research, including:
- In-depth interviews with leading KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR datasets
- Secondary research (e.g., peer-reviewed journal articles, third-party research databases)
Deliverables format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS Excel-based automated dashboard)
- Epidemiology (MS Excel; interactive tool)
- Executive Insights (PowerPoint presentation)
- Others: regular updates, customizations, consultant support
*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.
Salient features of Market Forecast model:
- 10-year market forecast (2026–2036)
- Bottom-up patient-based market forecasts validated through the top-down sales methodology
- Covers clinically and commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and patient share projections
- Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources & assumptions
- Graphical and tabular outputs
- Users can customize the model based on requirements
Key business questions answered:
- How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
- How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
- What is the 10-year market outlook for sales and patient share?
- Which events will have the greatest impact on the market’s trajectory?
- What insights do interviewed experts provide on current and emerging treatments?
- Which pipeline products show the most promise, and what is their potential for launch and future positioning?
- What are the key unmet needs and KOL expectations for target profiles?
- What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
- and more…
Moderate to Severe Dry Eye Disease Market Outlook and Forecast
Thelansis’s “Moderate to Severe Dry Eye Disease (DED) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Moderate to Severe Dry Eye Disease treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
Moderate to Severe Dry Eye Disease Overview
Moderate to severe dry eye disease is a multifactorial disorder of the ocular surface characterized by loss of tear-film homeostasis, tear instability, inflammation, and, in some patients, epithelial damage. Meibomian gland dysfunction, aqueous deficiency, and neurosensory abnormalities contribute to different disease phenotypes and can produce discomfort, burning, photophobia, and fluctuating vision. Artificial tears remain foundational, but management has expanded substantially beyond lubrication to include anti-inflammatory therapies, tear-evaporation control, and stimulation of endogenous tearing. Established treatments now include cyclosporine, lifitegrast, perfluorohexyloctane, and the cholinergic nasal spray varenicline. The treatment landscape broadened further in 2025 with FDA approval of acoltremon, a TRPM8 agonist that stimulates tear production and improved tear-production endpoints in randomized trials. Next-generation development is increasingly focused on phenotype-specific mechanisms, including kinase inhibition and other approaches targeting ocular-surface inflammation, tear secretion, and glandular dysfunction. OT202, a dual SYK/VEGFR-2 inhibitor, demonstrated activity in a 2026 Phase 2 study and has entered Phase 3 development. For stakeholders, moderate to severe DED represents an increasingly segmented therapeutic market in which the next advances are likely to come from matching mechanism to phenotype and achieving more durable restoration of tear-film and ocular-surface homeostasis.
Geography coverage:
G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven by robust research, including:
- In-depth interviews with leading KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR datasets
- Secondary research (e.g., peer-reviewed journal articles, third-party research databases)
Deliverables format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS Excel-based automated dashboard)
- Epidemiology (MS Excel; interactive tool)
- Executive Insights (PowerPoint presentation)
- Others: regular updates, customizations, consultant support
*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.
Salient features of Market Forecast model:
- 10-year market forecast (2026–2036)
- Bottom-up patient-based market forecasts validated through the top-down sales methodology
- Covers clinically and commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and patient share projections
- Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources & assumptions
- Graphical and tabular outputs
- Users can customize the model based on requirements
Key business questions answered:
- How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
- How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
- What is the 10-year market outlook for sales and patient share?
- Which events will have the greatest impact on the market’s trajectory?
- What insights do interviewed experts provide on current and emerging treatments?
- Which pipeline products show the most promise, and what is their potential for launch and future positioning?
- What are the key unmet needs and KOL expectations for target profiles?
- What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
- and more…
1. Key Findings and Analyst Commentary
- Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc..
2. Disease Context
- Disease definition, classification, etiology and pathophysiology, drug targets,etc.
3. Epidemiology
- Key takeaways
- Incidence / Prevalence
- Diagnosed and Drug-Treated populations
- Comorbidities
- Other relevant patient segments
4. Market Size and Forecast
- Key takeaways
- Market drivers and constraints
- Drug-class specific trends
- Country-specific trends
5. Competitive Landscape
- Current therapies
- Key takeaways
- Dx and Tx journey/algorithm
- Key current therapies – profiles and KOL insights
- Emerging therapies
- Key takeaways
- Notable late-phase emerging therapies – profiles, launch expectations, KOL insights
- Notable early-phase pipeline
6. Unmet Need and TPP Analysis
- Top unmet needs and future attainment by emerging therapies
- TPP analysis and KOL expectations
7. Regulatory and Reimbursement Environments (by country and payer insights)
8. Appendix (e.g., bibliography, methodology)
Table of contents (TOC)
1. Key Findings and Analyst Commentary
- Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc..
2. Disease Context
- Disease definition, classification, etiology and pathophysiology, drug targets,etc.
3. Epidemiology
- Key takeaways
- Incidence / Prevalence
- Diagnosed and Drug-Treated populations
- Comorbidities
- Other relevant patient segments
4. Market Size and Forecast
- Key takeaways
- Market drivers and constraints
- Drug-class specific trends
- Country-specific trends
5. Competitive Landscape
- Current therapies
- Key takeaways
- Dx and Tx journey/algorithm
- Key current therapies – profiles and KOL insights
- Emerging therapies
- Key takeaways
- Notable late-phase emerging therapies – profiles, launch expectations, KOL insights
- Notable early-phase pipeline
6. Unmet Need and TPP Analysis
- Top unmet needs and future attainment by emerging therapies
- TPP analysis and KOL expectations
7. Regulatory and Reimbursement Environments (by country and payer insights)
8. Appendix (e.g., bibliography, methodology)